Justin M. Balko
Vanderbilt University Medical Center
232 Papers
531 Citations
Justin M. Balko is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 54, co-authored 172 publications. Previous affiliations of Justin M. Balko include The Breast Cancer Research Foundation & Vanderbilt University.
Chat about Author
Papers
Role of JAK-STAT Pathway in Cancer Signaling
Na Luo,Justin M. Balko +1 more
- 01 Jan 2019
TL;DR: It remains to be determined precisely how the JAK-STAT pathway drives tumor development and oncogenic phenotypes and whether treatment with JAK inhibitors alone or in combination with inhibitors that target complimentary signaling pathways can be therapeutic in cancer patients and which patients are most likely to benefit.
21
Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum
Douglas B. Johnson,Jason Roszik,Alexander N. Shoushtari,Zeynep Eroglu,Justin M. Balko,Catherine F. Higham,Igor Puzanov,Sapna P. Patel,Jeffrey A. Sosman,Scott E. Woodman +9 more
TL;DR: Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum is compared.
Pharmacological Activation of cGAS for Cancer Immunotherapy
Kyle M. Garland,Jonah C. Rosch,Carcia S. Carson,Lihong Wang-Bishop,Ann Hanna,Sema Sevimli,Casey Van Kaer,Justin M. Balko,Manuel Ascano,John T. Wilson +9 more
TL;DR: NanoISD as mentioned in this paper is a nucleic acid immunotherapeutic, which overcomes critical delivery barriers that limit the activity of ISD and thereby promotes antitumor immunity through the pharmacological activation of cGAMP synthase at the forefront of the STING pathway.
17
Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.
Douglas B. Johnson,Garrett M. Frampton,Matthew J. Rioth,Erik Yusko,Riley Ennis,David Fabrizio,Joel R. Greenbowe,Siraj M. Ali,Dennie T Frederick,Igor Puzanov,Justin M. Balko,Justin M M Cates,Jeffrey S. Ross,Harlan Robins,Vincent A. Miller,Phil Stephens,Ryan J. Sullivan,Jeffrey A. Sosman,Christine M. Lovly +18 more
TL;DR: Responses to aPD1 had higher ML compared to non-responders in discovery, and RR was superior in high ML pts compared to intermediate/low as was progression-free survival (PFS).
16
A Critical Need for Better Cancer Immunotherapy Models: Are Organotypic Tumor Spheroid Cultures the Answer?
TL;DR: The use of organotypic cultures of tumors derived from mice and humans containing both tumor cells and cells from their local immune microenvironment are reported to recapitulate the in vivo use of immune checkpoint inhibitors and extend the application of this system to therapeutic combinations of immune checkpoints blockade and molecularly targeted agents.